Casper Pharma Private Limited

Casper Pharma Private Limited - pharma in Mumbai, Maharashtra, India. Directors, charges & compliance details.
CIN U24233MH2016PTC423891 Incorporated 13 January 2016 ROC Mumbai HQ Mumbai, Maharashtra, India
Merged Private Limited Company pharma
Revenue · FY 2024
₹30.43 Cr
▲ 151% YoY
Net loss · FY 2024
₹8.34 Cr
Net margin -27.4%
EBITDA · FY 2024
-₹2.51 Cr
EBITDA margin -8.3%
Authorised capital
₹26.1 Cr
Registered with MCA
Paid-up capital
₹26.08 Cr
Issued & subscribed
Company age
10 yrs
Est. 2016
Employees · EPFO
109
Provident fund records
Directors on board
3
As per MCA filings

About Casper Pharma Private Limited

Data last updated:

Casper Pharma Private Limited was a private limited company based in Mumbai, Maharashtra, India, operated as a subsidiary of Suven Pharmaceuticals Limited. The company has been amalgamated - it was merged with another entity and no longer exists as a separate legal entity. It operated in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 13 January 2016.

The company was registered with the Registrar of Companies (ROC), Mumbai, under CIN U24233MH2016PTC423891. Its GSTIN is 36AAGCC3439C1ZY (Telangana). The company held 2 GST registrations, all of them active.

The company had an authorised share capital of ₹26.1 Cr and a paid-up capital of ₹26.08 Cr. It was led by directors including Sudhir Kumar Singh (Whole-Time Director) and Venkatanaga Kali Vetukuri Vara Prasada Raju.

Its last annual general meeting (AGM) was held on 01 August 2024, and its latest financial statements are for the year ended 31 March 2024. The registered office was at Mumbai, Maharashtra.

As per the financials filed for FY 2024, the company reported a revenue of ₹30.43 Cr, reflecting significant growth compared to the previous year. For the same year it recorded a net loss of ₹8.34 Cr (net margin -27.4%) and EBITDA of -₹2.51 Cr (EBITDA margin -8.3%). Revenue has grown at a compounded annual rate (CAGR) of 71% over three years and 32% over five years.

The company had about 109 employees on its provident fund (EPFO) records before it was dissolved.

Court records list 1 case involving the company, including 1 filed by the company. The company has 3 deals on record (1 rights issue, 1 funding round, 1 secondary share transfer), with disclosed funding of ₹104.27 Cr; the latest was in June 2022. Its 4 peer companies in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 2 larger and 2 smaller; the largest is Puneet Laboratories Private Limited with revenue of ₹30.72 Cr. The company has 4 MSME Form 1 returns on record between 2020 and 2022, listing 42 overdue payments to 5 micro and small suppliers.

The last known website on record is cronuspharma.com.

Company details

CIN U24233MH2016PTC423891
Registration Number 423891
Incorporation Date 13 January 2016
ROC Mumbai
Listing Status Unlisted
Company Status Amalgamated
Parent Company Suven Pharmaceuticals Limited
Compliance Status Active Compliant

CIN history

Casper Pharma has one previous CIN (Corporate Identification Number): U24233TG2016PTC102713. The current CIN is U24233MH2016PTC423891, which is the unique identifier assigned by the Registrar of Companies.

CINStatus
U24233MH2016PTC423891Current
U24233TG2016PTC102713Previous

Contact details

Casper Pharma Private Limited's registered office is in Mumbai, Maharashtra. Its website is cronuspharma.com. Its e-mail address and telephone number are in the company report.

  • Email
  • Telephone
  • Registered Address
    215 Atrium C Wing 8th Floor 819 – 821, Andheri Kurla Road Chakala Andheri East, Mumbai, Maharashtra, India – 400093
  • Industry
    Pharma, Drug Formulation & Development

To see the full contact details of Casper Pharma Private Limited, buy the company report.

Comprehensive company report
Casper Pharma Private Limited - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Business activity

The main business activities of Casper Pharma are manufacturing and professional, scientific and technical. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products and other professional, scientific and technical activities. 2 activity segments are registered with the MCA.

Main activity group codeMain activityBusiness activity codeBusiness activityShare of turnover
CManufacturingC6Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products
MProfessional, Scientific and TechnicalM9Other professional, scientific and technical activities

To see the full business activity and turnover split of Casper Pharma Private Limited, buy the company report.

Financials of Casper Pharma Private Limited

FY 2024 filings available

Casper Pharma Private Limited reported revenue of ₹30.43 Cr (up 151% YoY) for FY 2024.

Revenue · FY 2024
₹30.43 Cr ▲ 151%
Net loss · FY 2024
₹8.34 Cr margin -27.4%
EBITDA · FY 2024
-₹2.51 Cr margin -8.3%

Compounded Annual Growth Rate (CAGR)

Revenue CAGR growth
1 year
▲ 151%
3 years · compounded
▲ 71%
5 years · compounded
▲ 32%
EBITDA CAGR growth
1 year
▲ 84%
3 years · compounded
▲ 15%
5 years · compounded
▼ 18%

Revenue has grown at a compounded annual rate (CAGR) of 32% over five years, including 151% growth in the latest year. EBITDA rose 84% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.

Financial Statement Summary

MetricsFY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Profit and Loss Statement
Revenue from Operations
Other Income
Total Revenue₹30.43 Cr
Cost of Materials Consumed
Employee Benefit Expense
Finance Costs
Depreciation and Amortisation
Other Expenses
Total Expenses
EBITDA-₹2.51 Cr
Profit Before Tax
Tax Expense
Net Profit (PAT)-₹8.34 Cr
Balance Sheet
Share Capital
Reserves and Surplus
Net Worth (Total Equity)
Long-term Borrowings
Short-term Borrowings
Trade Payables
Total Liabilities
Fixed Assets
Investments
Inventories
Trade Receivables
Cash and Bank Balance
Total Assets

Financial Ratios

MetricsFY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Profitability
EBITDA Margin-8.3%
Net Profit Margin-27.4%
Return on Equity (ROE)
Return on Capital Employed (ROCE)
Return on Assets (ROA)
Liquidity and Debt
Current Ratio
Quick Ratio
Debt-to-Equity Ratio
Interest Coverage Ratio
Efficiency and Growth
Asset Turnover
Receivable Days
Payable Days
Inventory Days
Revenue Growth
Net Profit Growth

To see the full financial statements and ratios of Casper Pharma Private Limited, buy the company report.

Board of directors of Casper Pharma Private Limited

Casper Pharma has 3 current directors and 9 former directors. Current directors are listed first, with their designation and appointment date.

Directors (as last reported)
NameDesignationAppointment DateTenureStatus
Venkatanaga Kali Vetukuri Vara Prasada RajuDirector01 Dec 20232 Years 11 MonthsAs last reported
Sudhir Kumar SinghWhole-Time Director01 Dec 20232 Years 11 MonthsAs last reported
Himanshu AgarwalAdditional Director01 Aug 20242 Years 3 MonthsAs last reported

Peer comparison

Casper Pharma Private Limited is compared with the 4 companies closest to it by revenue in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.

CompanyRevenueNet profitMarginGrowth (1 yr)EmployeesLocation
Puneet Laboratories Private Limited₹30.72 Cr (FY 2025)25.0%Mumbai, Maharashtra, India
Octavius Pharma Private Limited₹30.43 Cr (FY 2025)169.0%Ahmedabad, Gujarat, India
Casper Pharma Private Limitedthis company₹30.43 Cr (FY 2024)-₹8.34 Cr-27.4%151.0%109Mumbai, Maharashtra, India
Ronald Pharmaceuticals Private Limited₹30.33 Cr (FY 2024)-12.0%Vadodara, Gujarat, India
Signova Healthcare Private Limited₹30.25 Cr (FY 2025)24.0%Guwahati, Assam, India

To see the full peer comparison of Casper Pharma Private Limited, buy the company report.

Auditor

Casper Pharma Private Limited is audited by K.Nagaraju and Associates for the financial year 2024.

Auditor firmFinancial yearFirm registration number
K.Nagaraju and AssociatesFY 2024002270S

Shareholding

The shareholding of Casper Pharma Private Limited is on record for 5 financial years, the latest being FY 2024, split between promoters, domestic institutions, foreign institutions, public shareholders and others.

Shareholder categoryFY 2024FY 2023FY 2022FY 2021FY 2020
Promoters
Domestic institutional investors (DII)
Foreign institutional investors (FII)
Public
Others

To see the full shareholding pattern of Casper Pharma Private Limited, buy the company report.

Deals & funding

Casper Pharma Private Limited has 3 deals on record (1 rights issue, 1 funding round, 1 secondary share transfer), with disclosed funding of ₹104.27 Cr; the latest was in June 2022.

Total deals
3
Rights issue
1
Funding round
1
Secondary share transfer
1
Disclosed funding
₹104.27 Cr

Deals on record (3 of 3)

WhenDealAmountParties
Jun 2022Rights issue₹41.73 CrInvestors: Suven Pharmaceuticals Limited
Mar 2017Funding round₹104.27 CrInvestors: Casper Pharma Mauritius
Mar 2017Secondary share transferUndisclosedBuyer: Casper Pharma Mauritius, Casper Pharma Mauritius & Mallemputi Ramakrishna Chowdary
Seller: Casper Pharma LLC, Casper Pharma LLC & Mallemputi Ramakrishna Chowdury

Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.

MSME payment delays

Casper Pharma Private Limited has 4 MSME Form 1 returns on record between 2020 and 2022, listing 42 overdue payments to 5 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.

Suppliers with reported dues (5 of 5)

SupplierAmount dueDue sinceReported on
Kinelectro Lines India Private Limited
Vasco Scientifics Private Limited
an individual supplier
Omega Scientific Instruments Private Limited
Himedia Laboratories Private Limited

To see the full MSME payment records of Casper Pharma Private Limited, buy the company report.

Individuals and sole proprietors among the suppliers are not named.

Employees & EPFO

Casper Pharma Private Limited has a workforce of 109 employees on its EPFO records as of Jan 2025.

Employee count
109
Employee growth
3.8%

Headcount by financial year

Financial yearEmployees (EPFO)
FY 2024-25109
FY 2023-24
FY 2022-23
FY 2021-22
FY 2020-21
FY 2019-20

To see the full employee and EPFO history of Casper Pharma Private Limited, buy the company report.

GST

Casper Pharma has 2 GST registrations: 2 active.

Total GSTINs
2
Active
2
GSTINStateStatusRegistered on
36AAGCC3439C1ZYTelanganaActive01 Jul 2017
36AAGCC3439C2ZXTelanganaActive16 Mar 2021

To see the full GST registrations and return filing status of Casper Pharma Private Limited, buy the company report.

Recent activity

Casper Pharma Private Limited has 12 board changes on record since 2019: 3 appointments and 9 cessations. The latest: Himanshu Agarwal was appointed as Additional Director on 01 Aug 2024.

AGM
Casper Pharma Private Limited last Annual general meeting of members was held on 01 Aug 2024 as per latest MCA records.
Appointed
Himanshu Agarwal was appointed as Additional Director.
Filing
Casper Pharma Private Limited has filed its annual Financial statements for the year ended 31 Mar 2024 with Roc Mumbai.
Ceased
Sudhir Kumar Singh ceased to be Additional Director.
Ceased
Venkatanaga Kali Vetukuri Vara Prasada Raju ceased to be Additional Director.
Appointed
Sudhir Kumar Singh was appointed as Whole-Time Director.
Appointed
Ceased
Hanumantha Rao Kokkonda ceased to be Additional Director.
Ceased
Lakshmana Rao Veeramachaneni ceased to be Additional Director.
Ceased
Sunder Venkatraman ceased to be Additional Director.
Ceased
Kavuru Vimal Kumar ceased to be Director.
Ceased
Mallemputi Ramakrishna Chowdary ceased to be Director.

3 earlier events are in the company report.

Frequently asked questions

Casper Pharma has been "Amalgamated" (merged) as per MCA records. The company was combined with another entity and no longer exists as a separate legal entity. Business activities, if any, continue under the successor entity.

Casper Pharma was a private limited company based in Mumbai, Maharashtra, India. The company worked in drug formulation and development, within the pharma industry. It was incorporated on 13 January 2016 and is registered under CIN U24233MH2016PTC423891. The company is recorded as amalgamated in MCA records and no longer exists as a legal entity.

Casper Pharma was incorporated on 13 January 2016. It is registered with the Registrar of Companies, Mumbai.

Casper Pharma had 3 directors:

The CIN (Corporate Identification Number) of Casper Pharma is U24233MH2016PTC423891. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

The registered office of Casper Pharma is at 215 Atrium C Wing 8th Floor 819 – 821, Andheri Kurla Road Chakala Andheri East, Mumbai, Maharashtra, India – 400093.

Casper Pharma can be reached through the website cronuspharma.com. Its registered office is in Mumbai, Maharashtra, India.

The latest financial statements of Casper Pharma on record with the MCA are for the year ended 31 March 2024. Its last annual general meeting was held on 01 August 2024. Year-wise statements from FY 2016 are in the company report.

The GSTIN of Casper Pharma is 36AAGCC3439C1ZY, registered in Telangana. The company has 2 GST registrations in all, of which 2 are active. Other active GSTINs include 36AAGCC3439C2ZX (Telangana).

Casper Pharma operated in the pharma industry, in the drug formulation and development segment.

Casper Pharma has 3 deals on record (1 rights issue, 1 funding round, 1 secondary share transfer), with disclosed funding of ₹104.27 Cr; the latest was in June 2022.

The peers of Casper Pharma by revenue are Puneet Laboratories Private Limited, Octavius Pharma Private Limited, Ronald Pharmaceuticals Private Limited, Signova Healthcare Private Limited, all in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).